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Abstract
Genetic biomarkers are sought to personalize treatment of patients with rheumatoid arthritis
(RA), given their variable response to TNF inhibitors (TNFi). However, no genetic biomaker
is yet sufficiently validated. Here, we report a validation study of 18 previously reported
genetic biomarkers, including 11 from GWAS of response to TNFi. The validation was
attempted in 581 patients with RA that had not been treated with biologic antirheumatic
drugs previously. Their response to TNFi was evaluated at 3, 6 and 12 months in two ways:
change in the DAS28 measure of disease activity, and according to the EULAR criteria for
response to antirheumatic drugs. Association of these parameters with the genotypes,
obtained by PCR amplification followed by single-base extension, was tested with regres-
sion analysis. These analyses were adjusted for baseline DAS28, sex, and the specific
TNFi. However, none of the proposed biomarkers was validated, as none showed associa-
tion with response to TNFi in our study, even at the time of assessment and with the out-
come that showed the most significant result in previous studies. These negative results are
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notable because this was the first independent validation study for 12 of the biomarkers, and
because they indicate that prudence is needed in the interpretation of the proposed bio-
markers of response to TNFi even when they are supported by very low p values. The
results also emphasize the requirement of independent replication for validation, and the
need to search protocols that could increase reproducibility of the biomarkers of response to
TNFi.
Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune disease mainly characterized by inflam-
mation of synovial joints [1]. If poorly treated, RA is very painful and incapacitating, and it
can lead to joint deformities, loss of job and mobility, and premature death. Currently, the
prognosis is much better than before the turn of the XXI century thanks to drugs that are spe-
cifically targeted to immune mediators [1,2]. The first drugs of this class were the TNF inhibi-
tors (TNFi), infliximab, and adalimumab, which are monoclonal anti-TNF antibodies, and
etanercept, which is a recombinant soluble TNF receptor. Now, more TNFi are available
together with other drugs targeting IL6, B cells, T cells or intracellular kinases. This range of
drugs is welcomed because none of them is effective in all patients. Typically about 30% of the
patients fail to respond to any of the drugs, and an additional 30% of patients show only a par-
tial response. This between-patient variability has not prevented the rheumatologists to aim
for remission or low disease activity, which they seek by changing from one drug to another,
and by combining them with conventional antirheumatic drugs [1,2]. The election of drug fol-
lows a trial and error approach, which is very unsatisfactory because these drugs are expensive
and have potential side effects. Furthermore, delayed control of the disease worsens long term
prognosis. A very attractive alternative will be to use biomarkers for personalizing the treat-
ment [3,4].
An important effort has been directed to the discovery of genetic biomarkers of response to
TNFi [5,6]. It has involved candidate gene studies and Genome-Wide Association studies
(GWAs). This effort has led to some remarkable findings: the two SNPs (rs3794271 and
rs284511) that have achieved association with response to TNFi below the GWAS significance
threshold of p< 5 x10-8 [7,8]; the association of the PTPRC locus in three large independent
studies [9–11]; and two other SNPs (rs6427528 and rs113878252) with very convincing evi-
dence of association with response to etanercept [12,13]. Regrettably, none of these results or
any of the other proposed biomarkers is sufficiently validated, either because an independent
validation is still pending, or because of lack of replication in other studies.
Here, our aim has been to validate 18 SNPs that were previously associated with response to
TNFi in RA [7,8,14–18]. This list of SNPs includes some of the most promising genetic bio-
markers mentioned above [7,8], and others [14–18]. Unfortunately, none of the SNPs showed
association with response to TNFi in our RA patients.
Materials and methods
Patients
The study population consisted of 581 patients with RA according to the ACR 1987 criteria
[19]. They were treated with an TNFi as the first targeted antirheumatic drug by indication of
the attending rheumatologist. This treatment indication was made with independence of the
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study. Recruitment of samples was approved by the local ethics committees and patients gave
their written informed consent. The study was conducted according to the principles of the
Declaration of Helsinki (2013) and was approved by the Research Ethics Committee of Galicia
(Spain, code 2014/387). The patients were of European origin (Spanish ancestry = 530 and
Greek ancestry = 51). Change in Disease Activity Score 28 joints (ΔDAS28 = DAS28baseline
− DAS28follow-up) was used as the primary outcome. The DAS28 composite index includes
erythrocyte sedimentation rate, self-reported global patient health, and counts of swollen joints
and of tender joints among 28 selected joints [20]. A score over 5.1 indicates high disease activ-
ity, whereas below 3.2 indicates low activity. In addition, response according to the European
League Against Rheumatism (EULAR) criteria was assessed [21]. Non-responders are defined
as patients showing 0.6 improvement from baseline DAS28, or showing modest improve-
ment, 1.2, but remaining with high disease activity, DAS28 > 5.1. Good responders show
DAS28 3.2 and improvement from baseline > 1.2. The remaining patients are considered
moderate responders.
Genotyping
Eighteen SNPs were selected because of previous association with response to TNFi in RA irre-
spective of ethnicity or country of origin (Table A in S1 Text) [7,8,14–18]. Genotyping was
conducted by multiplex PCR amplification followed by single-base extension with the SNaP-
shot Multiplex Kit (Applied Biosystems, Foster City, California). The primers, probes and
detailed protocols used for these analyses are available from the authors upon request. Replica-
tion in duplicate genotyping reactions of 10% of the samples, genotype call rate 94%, con-
cordance with the Hardy–Weinberg equilibrium (p<0.01), and with SNP frequencies in the
HapMap collections [22], were used for quality control (Table B in S1 Text). Two SNPs
(rs10520789 and rs1679568) did not follow the Hardy–Weinberg equilibrium and were
excluded. The R statistical package SNPAssoc was used for Hardy-Weinberg equilibrium
assessment and allelic frequency calculation [23].
Statistical analysis
The main outcome of treatment was ΔDAS28 at 6 months. EULAR non-responders compared
with responders (good + moderate) or non-responders compared with good responders (mod-
erate responders left out) at any time, and ΔDAS28 at 3 or 12 months were considered second-
ary outcomes. Linear and logistic regression models for ΔDAS28 and EULAR response were
fitted, respectively. Genotypes were considered in accordance with an additive genetic model
of minor allele counts (0, 1 or 2). Therefore, positive regression coefficients indicate a better
response associated with minor allele additive effects. Analyses were adjusted for baseline
DAS28, sex and the specific TNFi. Results were interpreted considering the number of tests
following the Bonferroni approach, consistence of results with the different outcomes, inde-
pendence from confounding variables, and previous reports. Statistica 7.0 software (Statsoft,
Tulsa, OK, USA) was used for the analyses.
Data availability: all data included in this study is available in the S1 Dataset.
Results
Characteristics of the RA patients
Fifteen patients lacking baseline DAS28 information were excluded. The remaining 566 RA
patients showed the demographic and clinical characteristics shown in Table 1. They presented
a severe disease before the start of TNFi, as indicated by the frequent presence of erosions and
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of the specific RA autoantibodies, and by the high mean disease activity (mean DAS28 > 5.1)
that was not controlled by previous treatments. The patients were evaluated during the course
of treatment with infliximab (n = 381), adalimumab (n = 152) or etanercept (n = 33). Response
to treatment was evaluated at 3, 6 or 12 months of follow-up with information available for a
variable number of patients at each point (n = 289 at 3 months, 532 at 6 months and 365 at 12
months). All of them except 2.6% received TNFi together with conventional antirheumatic
drugs. The treatment was associated with a significant decrease in RA activity, which was more
Table 1. Clinical characteristics of the 566 patients with RA.
Characteristic Value
Women, N (%) 478 (84.5)
Age at treatment, mean ± SD 52.3 ± 12.8
Rheumatoid factor positive, N (%) 410 (72.6)
Anti-CCP positive, N (%) 328 (67.8)
Erosive arthritis a, N (%) 284 (68.4)
Smoking a, N (%) 57 (17.1)
Concomitant cDMARD a, N (%) 455 (97.4)
TNFi, N (%)
infliximab 381 (67.4)
adalimumab 152 (26.8)
etanercept 33 (5.8)
Baseline ESR a, mean ± SD 38.3 ± 22.9
Baseline CRP a, mean ± SD 11.9 ± 20.1
Baseline HAQ a, mean ± SD 1.54 ± 0.68
DAS28, mean ± SD
Baseline 5.7 ± 1.2
3 months 4.1 ± 1.4
6 months 3.8 ± 1.4
12 months 3.7 ± 1.5
EULAR response, N (%)
3 months, N = 289
Good responder 72 (25.0)
Moderate 150 (52.0)
Non responder 67 (23.0)
6 months, N = 532
Good responder 187 (35.1)
Moderate 227 (42.7)
Non responder 118 (22.2)
12 months, N = 365
Good responder 150 (41.1)
Moderate 138 (37.8)
Non responder 77 (21.1)
Abbreviations: N, number; SD, standard deviation; anti-CCP, anti-cyclic citrullinated peptide antibodies; cDMARDs,
conventional disease-modifying anti-rheumatic drugs; HAQ, health assessment questionnaire; DAS28, Disease
Activity Score 28 joints; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; EULAR, The European
League Against Rheumatism.
a Data from <85% of the patients were available: 415 for erosive arthritis, 334 for smoking, 467 for concomitant
cDMARDs, 375 for baseline ESR, 378 for baseline CRP and 372 for baseline HAQ.
https://doi.org/10.1371/journal.pone.0196793.t001
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marked during the first 3 months than at later times. The mean DAS28 value remained in a
narrow range from the 3rd month onward (4.1 to 3.7). In a similar way, the frequency of non-
responders according to the EULAR criteria was very uniform at the three assessment times
(21.1 to 23.0%).
Analysis of association with response to TNFi
Univariate analyses identified clinical and demographic variables that were associated with
ΔDAS28 at 6 months (Table 2). The strongest association was found between ΔDAS28 and
baseline DAS28. It was followed by the specific TNFi used, and by sex. These three variables
retained association in the multivariate analysis including them (Table 2). Therefore, they
were retained as potential confounders for all analyses. No association between ΔDAS28 at 6
months and age at the start of treatment, time since disease onset, presence of autoantibodies
(rheumatoid factor or anti-cyclic citrullinated peptides) or erosions, smoking, concomitant
antirheumatic drug, or baseline disability was observed (Table 2).
Two of the 18 SNPs failed quality control and were excluded from analysis. None of the
remaining 16 SNPs was associated with response to TNFi in our patients when the threshold
of significance was adjusted for the number of tests (p< 0.003). Specifically, none of the SNPs
was associated with the primary outcome, ΔDAS28 at 6 months, or with the secondary out-
comes ΔDAS28 at 3 or at 12 months, even at the level of the uncorrected 0.05 p value (Table 3).
Regarding the secondary outcomes based in EULAR criteria, only a SNP showed nominal
association with EULAR non-response (rs10925026 at 6 months), but it was not below the
adjusted p value, and the direction of changes was not consistent at other assessment times
(Table 4).
Direct comparison with previous studies
We also checked the consistency of our results with the previous studies in which the biomark-
ers had been proposed [7,8,14–18]. This implied to consider the same time of assessment, mea-
sure of response, reference allele, and direction of change (improvement or lack of
improvement) that produced the lowest p value in previous studies (Table 5). In addition, we
considered the comparability of the minor allele frequencies (MAF), the proportions of
Table 2. Characteristics of the patients associated with ΔDAS28 at 6 months in either univariate or multivariate regression.
Univariate Multivariate
Characteristic β (SE) p β (SE) p
Sex -0.07 (0.04) 0.09 -0.09 (0.04) 0.025
Age at treatment -0.006 (0.05) 0.9
Time since diagnosis -0.06 (0.05) 0.2
Rheumatoid factor -0.01 (0.04) 0.8
Anti-CCP -0.03 (0.05) 0.6
Erosive arthritis -0.06 (0.05) 0.3
Smoking -0.06 (0.06) 0.3
Concomitant cDMARD 0.02 (0.05) 0.6
infliximab/other 0.10 (0.04) 0.02 0.19 (0.04) 0.000002
Baseline HAQ 0.06 (0.05) 0.2
Baseline DAS28 0.42 (0.04) < 10−16 0.47 (0.04) < 10−16
Abbreviations: β, coefficient of the regression; SE, standard error; anti-CCP, anti-cyclic citrullinated peptide antibodies; cDMARDs, conventional disease-modifying
anti-rheumatic drugs; HAQ, health assessment questionnaire; DAS28, Disease Activity Score 28 joints.
https://doi.org/10.1371/journal.pone.0196793.t002
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patients on each specific TNFi and on concomitant treatment with cDMARD, and the fraction
of ACPA positive patients, as all these factors could influence the association.
First, we compared the direction of effect. Only 5 of the 12 SNPs, in which this information
was available from the previous studies, showed consistency in direction between our results
Table 3. Results of the linear regression between the studied SNPs and ΔDAS28 at 3, 6 and 12 months of treatment a.
3 mo. 6 mo. 12 mo.
Locus SNP Allele β b p β b p β b p
ALPL rs885813 C - 0.04 0.5 0.01 0.8 - 0.05 0.3
rs885814 T - 0.03 0.5 0.0006 1.0 - 0.06 0.2
CARD8 rs10403848 A - 0.08 0.13 - 0.02 0.5 - 0.03 0.6
rs11672725 T - 0.01 0.8 - 0.01 0.9 - 0.03 0.5
GFRA1 rs7070180 T - 0.02 0.7 - 0.07 0.07 - 0.005 0.9
LRPAP1 rs3468 A 0.02 0.7 0.03 0.5 - 0.04 0.3
LRRC55 rs717117 G - 0.01 0.8 - 0.02 0.6 0.03 0.6
MAP2K6 rs11870477 C 0.02 0.7 0.02 0.6 0.05 0.3
MAP3K7 rs284511 T - 0.03 0.6 - 0.05 0.2 - 0.05 0.3
rs284515 G - 0.06 0.3 0.01 0.8 - 0.04 0.4
NLRP3 rs4925659 A - 0.03 0.6 - 0.01 0.7 - 0.004 0.9
rs4925648 T 0.03 0.5 0.05 0.2 - 0.04 0.4
rs10925026 C - 0.01 0.8 - 0.02 0.7 0.02 0.7
rs4612666 T - 0.03 0.6 0.02 0.7 - 0.005 0.9
NR2F2 rs16973982 C 0.06 0.3 0.07 0.08 0.07 0.11
PDE3A-SLCO1C1 rs3794271 G - 0.04 0.5 - 0.01 0.7 0.05 0.3
a Linear regression was adjusted by baseline DAS28, TNFi and sex.
b All β standard errors were = 0.05 for analyses at 3 and 12 months, and they were = 0.04 for all analyses at 6 months.
https://doi.org/10.1371/journal.pone.0196793.t003
Table 4. Results of the logistic regression between the studied SNPs and the non-responder EULAR class at 3, 6 and 12 months of treatment a.
3 mo. 6 mo. 12 mo.
SNP Allele OR (CI 95%) p OR (CI 95%) p OR (CI 95%) p
rs885813 C 0.9 (0.5–1.5) 0.6 1.0 (0.6–1.5) 0.8 1.1 (0.6–1.8) 0.8
rs885814 T 1.0 (0.6–1.6) 1.0 1.0 (0.7–1.4) 0.9 1.4 (1.0–2.1) 0.07
rs10403848 A 1.3 (0.7–2.1) 0.4 1.2 (0.8–1.8) 0.3 1.4 (0.8–2.3) 0.2
rs11672725 T 1.1 (0.7–1.7) 0.7 1.0 (0.7–1.5) 0.8 1.2 (0.8–1.9) 0.4
rs7070180 T 1.2 (0.7–2.1) 0.6 1.3 (0.9–2.1) 0.2 1.0 (0.6–1.6) 0.9
rs3468 A 0.9 (0.5–1.5) 0.6 0.7 (0.5–1.1) 0.12 0.9 (0.5–1.6) 0.8
rs717117 G 1.5 (0.6–3.7) 0.4 1.2 (0.6–2.3) 0.6 0.9 (0.3–1.9) 0.7
rs11870477 C 1.2 (0.7–2.1) 0.6 1.0 (0.6–1.5) 0.9 0.7 (0.4–1.3) 0.3
rs284511 T 1.3 (0.9–1.9) 0.3 1.0 (0.8–1.4) 0.9 1.2 (0.8–1.7) 0.4
rs284515 G 1.2 (0.7–2.0) 0.5 0.9 (0.6–1.4) 0.7 1.4 (0.8–2.3) 0.3
rs4925659 A 1.3 (0.9–2.0) 0.2 0.8 (0.6–1.1) 0.2 1.2 (0.8–1.8) 0.4
rs4925648 T 0.9 (0.4–1.7) 0.7 0.7 (0.4–1.1) 0.10 1.0 (0.6–1.7) 1.0
rs10925026 C 0.9 (0.6–1.4) 0.6 1.4 (1.0–1.9) 0.037 0.9 (0.6–1.3) 0.5
rs4612666 T 1.3 (0.9–2.0) 0.2 0.9 (0.6–1.3) 0.5 1.0 (0.7–1.5) 1.0
rs16973982 C 1.1 (0.5–2.0) 0.9 0.9 (0.5–1.5) 0.7 0.9 (0.5–1.6) 0.6
rs3794271 G 1.2 (0.8–1.8) 0.4 0.7 (0.5–1.0) 0.06 0.8 (0.5–1.2) 0.4
a Logistic regression was adjusted for baseline DAS28, the specific TNFi and sex
Abbreviations: OR, odds ratio; CI, confidence interval
https://doi.org/10.1371/journal.pone.0196793.t004
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and the previous reports, one was completely neutral (rs4925648), and the other 6 SNPs showed
opposite direction (Table 5). Next, we focused in the effect sizes of the 5 SNPs showing the same
direction of effect in the two studies. For the 2 SNPs assessed as ΔDAS28 (rs7070180, rs284511),
the regression coefficients were markedly lower in our study than in the previous ones. Also, for
the 3 SNPs assessed according with EULAR criteria (rs4612666, rs717117, rs3794271), the odds
ratios were notably nearer 1.0 in our results than in previous reports. Information of direction
or size of effect for the remaining 4 SNPs (rs885813, rs885814, rs11870477, rs16973982) was not
available in the previous report [14], and only comparison of the p values was possible. The con-
trast between p values for these 4 SNPs was very notable, because none of them showed even a
trend to association in our results, but showed p values 1 x10-5 in the previous report [14].
We also found the MAF of most of the SNPs in our patients were similar to the observed in
the previous studies reporting association (Table A in S1 Text). All the MAF were less than
20% different from the previously reported in Europeans, except for rs717117 that was about
half as frequent in our patients as in the Danish patients from the previous report [14]. The
MAF differences were larger (+30% and -33%) for the two SNPs, rs284511 and rs284515, pre-
viously reported in Japanese patients [8]. Additionally, our patients were comparable with pre-
vious ones in the percentage receiving concomitant treatment with cDMARD, which ranged
from 73 to 87% except for a study with all patients on combined treatment [16], and in the
fraction of ACPA positive patients, which ranged from 59 to 89% (Table B in S1 Text).
Table 5. Direct comparison of results for the same outcomes in the current and previous studies. Outcomes were either ΔDAS28 at 3 or 6 months, or the EULAR cri-
teria, which were used as a comparison of non-responders (NR) with responders (good + moderate responders (GR + M)) at 3 months, or a comparison of NR with GR
either at 3 or 6 months. Only previous studies with significant associations are included. Comparison of effect size and direction, and of p values.
Effect size p
Outcome SNP Current Previous Current Previous Reference
ΔDAS28 β β
3 mo. rs885813 - 0.04 - 0.5 1.0 x10-5 14
rs885814 - 0.03 - 0.5 5.5 x10-6 14
rs10403848 - 0.08 0.18 0.13 0.02 15
rs11870477 0.02 - 0.7 3.3 x10-6 14
rs284515 - 0.06 0.35 0.3 5.6 x10-5 8 a
rs16973982 0.06 - 0.3 2.8 x10-6 14
6 mo. rs7070180 0.07 b 0.30 0.07 6.4 x10-5 16
rs284511 0.05 c 0.41 0.2 2.5 x10-8 8
NR vs. (GR+M) OR OR
3 mo. rs11672725 0.92 b 1.05 0.7 0.032 15
rs4925659 0.77 b 1.06 0.2 0.006 15
rs10925026 1.12 b 0.94 0.6 0.017 15
rs4612666 0.75 b 0.64 0.2 0.025 17
NR vs. GR
3 mo. rs717117 1.36 10.7 0.4 9.6 x10-6 14
rs4925648 1.00 b 1.15 1.0 0.035 15
rs3794271 1.28 3.2 0.3 3.5 x10-6 14
2.63 1.7 x10-5 7
6 mo. rs3468 0.8 1.28 0.4 0.003 18
a An even lower p value was reported in this study with the joint analysis of response at 3 and at 6 months.
b Referred to the opposite outcome to match previous analysis.
c Referred to the opposite allele, because the minor allele is different in the Japanese and the Europeans.
https://doi.org/10.1371/journal.pone.0196793.t005
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However, there was a lot of heterogeneity in the distribution of the specific TNFi (Table B in
S1 Text). Five studies (three of which were from the same patient registry) showed an even dis-
tribution in three fractions receiving either infliximab, adalimumab or etanercept
[7,15,17,18,24]. Two studies, including the current one, showed about 70% of patients on
infliximab and 25% on adalimumab with only 5% on etanercept [14]. Other two studies were
dominated by patients on infliximab or etanercept, with only 10% on adalimumab [8,16]; and
finally, a unique study included 65% of patients treated with adalimumab, with the remaining
patients distributed between the other two TNFi [25].
Discussion
Our attempt to validate genetic biomarkers of response to TNFi has led to increased doubts on
their status. Consequently, our results emphasize the need of independent validation of all
genetic findings, even of those that reach the GWAS level of significance. In addition, the
results call for a revision of the ideas justifying the search of genetic biomarkers, and to con-
sider possible ways to improve their reproducibility.
At a first glance, the most surprising lack of association in our patients corresponds to
rs3794271 in PDE3A-SLCO1C1, and rs284511 near MAP3K7, because the two SNPs have
reached p< 5 x10-8, the GWAS threshold of significance, in previous studies [7,8]. A more
detailed consideration, yet, indicates that our results are not so striking. In relation with
rs3794271, because its role as biomarker has already been contradicted by lack of association
with response to TNFi in 1750 UK patients with RA [24]. This study was much larger than the
two studies that discovered this putative biomarker (196 Danish and 315 Spanish patients,
respectively) [7,14]. A fraction of the patients in the UK study differed from the patients in the
two other studies, but these differences seemed irrelevant for the lack of replication [24]. Our
study, which was in all respects comparable to the Danish and Spanish studies [7,14], rein-
forces this conclusion. In relation to the other SNP, rs284511 (and rs284515 in the same
MAP3K7 locus), our study is the first independent validation attempt, but the possibility of an
ethnic factor in the discordant results should be reckoned as it was discovered in Japanese
patients [8]. An ethnic factor is well known in the genetic component of RA, where most loci
are shared between Europeans and Asians, but 5 loci are specific to one or the other ethnic
group [26]. This possibility was also suggested by the difference in MAF of the two MAP3K7
SNPs between our study and the Japanese patients, which was larger than the present for SNPs
from European reports. Asian specificity of the MAP3K7 association would explain our result
and that none of the previous GWAS in Europeans have mentioned these two SNPs [12–
14,16,25,27].
Other 5 SNPs were initially discovered in the same Danish GWAS that uncovered the
already discussed SNP in PDE3A-SLCO1C1 [14]. All of them showed p< 10−4 in the 196
patients of that study, but none obtained subsequently any support. The low frequency
rs717117 SNP has never been reported again. None of the other 4 SNPs was associated with
response to TNFi in a GWAS of 882 RA patients from the Netherlands [25], and rs11870477
was not replicated in 315 patients of a Spanish study [7]. This latter study did not analyze the
other 4 SNPs.
More intriguing is the status of rs7070180 in the GFRA1 gene, whose investigation has been
prone to mishaps. This SNP showed significant association (p< 10−4) with response to TNFi
in stages 1 and 2 of a UK study (945 patients in total), but its assay failed in stage 3 [16]. Subse-
quent studies never mentioned it, until a recent GWAS in Japanese patients [8]. This study
identified rs1679568, other SNP in the same GFRA1 locus, as associated with response to TNFi
with p< 10−6. The authors took this result as concordant with the rs7070180 association in
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UK patients because rs7070180 was not genotyped or imputed in the Japanese patients [8].
Regrettably, our results were also incomplete. On one side, the rs1679568 assay did not pass
quality control in our study. On the other, our results for rs7070180 where inconclusive: we
found a smaller effect size than in Plant et al. (β = 0.07 vs. 0.30) [16], but concordant direction
of effect and a trend to association (p = 0.07). Consequently, we think the status of this locus is
still ambiguous.
The remaining seven SNPs had shown association with response to TNFi that was signifi-
cant according with the criteria applied to their discovery studies [15,17,18], but that was less
convincing from the statistical point of view (p values between 0.05 and 0.003) than the SNPs
discussed above. The additional criteria leading to take these SNPs as potential biomarkers
included functional studies that established a correlation between the SNPs and molecular
changes that seemed important for RA pathogenesis. Six of these SNPs are located in two inter-
esting genes from the point of view of RA pathogenesis, NLPR3 (four SNPs) and CARD8 (two
SNPs). Five of them were associated with response to TNFi in a study of 1278 UK patients
with RA [15]. In the same study, the authors found differences in expression of the NLPR3 and
CARD8 genes between monocytes from RA patients and controls, and association linking the
SNPs with the expression of NLPR3 and CARD8 in monocytes [15]. Further support for associ-
ation of NLPR3 with the response to TNFi was provided by an independent study of 538 Dan-
ish patients with RA [17]. In this study, only a NLPR3 SNP (rs4612666) was tested, but it
showed association. The final SNP of the seven in this group (rs3468) was selected from a very
attractive study. In it, the A allele of rs3468 was identified primarily as the SNP that was most
associated (p< 1.1 x10-6) with increased DNA methylation at two cis-CpG sites on the
LRPAP1 gene, which, in turn, was strongly associated with response to etanercept (p< 1.7
x10-8). In addition, there was weak genetic association (p< 0.05) of the A allele of rs3468 with
non-response to TNFi in two sets of RA patients (with 56 and 1204 patients, respectively) [18].
Therefore, the relationship was established mainly as indirect. Our results were clearly con-
trary to the previously reported and, together with lack of replication of the other six SNPs in
this group, reinforce the well-known fact that the main determinant of reproducibility of
genetic associations is the level of statistical association [28,29].
In addition to the specific comments for each SNP of the previous paragraphs, there are
other factors that could have contributed to the lack of reproducibility of the results. The possi-
ble impact of differences in ethnicity has already been discussed in relation with the MAP3K7
SNPs. All other SNPs were described in studies done with European patients and ethnicity is
less likely a factor for them. In addition, MAF were comparable for all the SNPs from Euro-
pean studies except for rs717117, whose low frequency in our patients (MAF = 5.3%) made for
a lower statistical power than in the original study (MAF = 11%). Other study characteristics
that could impinge in the results, the fraction of patients on concomitant treatment with
cDMARD and the fraction with ACPA, can also be dismissed as differential because they were
comparable between studies. Nevertheless, there was marked variability in the distribution of
the specific TNFi that the patients had received. No common pattern was found among the
reports, with our patients being only comparable with a previous study. The two sets of
patients showed predominant treatment with infliximab and few patients on etanercept. The
other studies were characterized by a variety of TNFi distributions. Considering that some
patients who are resistant to a TNFi respond to a different one, it is possible that these differ-
ences in representation of the various TNFi have contributed to the lack of replication.
Our results invite to reconsider the search of genetic biomarkers of response to TNFi. The
first point to ponder is the heritability of the phenotype, which was unknown until recently,
when a familial component in the response to TNFi was demonstrated [30], and the heritabil-
ity of ΔDAS28 was quantified (h2 from 0.59 to 0.71 in different estimations) as sufficient for
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genetic studies [31]. However, change in the number of swollen joints or in the number of ten-
der joints, which are components of DAS28, showed larger heritability than ΔDAS28 suggest-
ing that they could be used as more discriminant outcomes of treatment [31]. Possible benefits
of these alternative outcomes remain still untested, and we could not assess their performance
in our study because they are not available in many of our patients. Other improvement that
has been proposed consist in reducing within patient variability by using as outcome the aver-
ages of frequently repeated response assessments [32]. Another point of interest is the struc-
ture of the genetic component of response to TNFi, which has been clarified by recent studies
[27,33,34]. This component is not significantly shared with the RA susceptibility loci, either
taken individually, or in combination [9,33]. In addition, rare variants with strong effect do
not contribute significantly to the response to TNFi [34]. Therefore, only common variants
unrelated with RA susceptibility seem likely, but the effect of each of them appears to be small.
This is the conclusion of a thorough study, with many analysis tools and by multiple teams,
done in 2706 RA patients [27]. This conclusion emphasizes the need to continue searching
with more GWAS, which are very powerful for identifying common genetic variants but need
to be large to find those of small effect. Also, it emphasizes the importance of pursuing the best
supported biomarkers to establish their value, as PTPRC [9–11], a recently discovered SNP
associated with response to etanercept [13], the SNPs associated in the Japanese GWAS [8], or
other SNPs with significant association in recent meta-analysis [5]. In addition, it is to be
expected that biomarkers will be searched in other ethnicities as we lack information about
many populations that could show particular biomarkers of value for the RA patients from the
corresponding genetic background.
The available evidence, therefore, shows the need for prudence in claiming new biomarkers,
the requirement for independent replication of all previous findings, and the convenience of
exploring the possibility of drug-specific biomarkers among the TNFi, and the use of outcomes
with high heritability, as change in the number of swollen or tender joints, and of using aver-
ages of repeated assessment of these outcomes, to increase the success of genetic studies. Prog-
ress along these lines will require new and large collections of patients.
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